|
|
Vaccine Detail
|
EP-2101 Vaccine |
| Vaccine Information |
- Vaccine Name: EP-2101 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Product Name: EP-2101, OSE 2101
- Vaccine Ontology ID: VO_0007081
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: Trp53, CEA, ERBB2, MAGEA3
- human TP53 (P53)
gene engineering:
- CEACAM5 - obsolete
gene engineering:
- Type: peptide vaccine preparation
- Description:
- Detailed Gene Information: Click Here.
- ERBB2
gene engineering:
- Type: Recombinant protein preparation
- Description: (Beebe et al., 2008)
- Detailed Gene Information: Click Here.
- MAGEA3
gene engineering:
- Type: Recombinant protein preparation
- Description: (Beebe et al., 2008)
- Detailed Gene Information: Click Here.
- MAGEA2
gene engineering:
- Type: Recombinant protein preparation
- Description: (Beebe et al., 2008)
- Detailed Gene Information: Click Here.
- Description: This is for Lung Cancer (NCT02654587). A proprietary cancer DNA vaccine that contains multiple natural and modified epitopes derived from the four tumor associated antigens, CEA, HER2/neu, p53, and MAGE 2/3. EP-2101 also includes CAP1-6D, a heteroclitic CEA analog, and PADRE, a proprietary universal T-cell epitope that serves to enhance the immunogenicity of the epitopes. This agent has been shown to elicit cytotoxic T-lymphocyte responses against tumor cells expressing these multiple epitopes. (NCIT_C26645).
|
| Host Response |
|
|
| References |
Beebe et al., 2008: Beebe M, Qin M, Moi M, Wu S, Heiati H, Walker L, Newman M, Fikes J, Ishioka GY. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy. Human vaccines. 2008; 4(3); 210-218. [PubMed: 18382135].
NCIT_C26645: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26645]
NCT02654587: [https://clinicaltrials.gov/ct2/show/NCT02654587]
|
|
